Clinical Trials Logo

Refractory Follicular Lymphoma clinical trials

View clinical trials related to Refractory Follicular Lymphoma.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT02989532 Active, not recruiting - Clinical trials for Recurrent Grade 2 Follicular Lymphoma

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

Start date: April 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ibrutinib works in treating patients with follicular lymphoma that has come back after a period of improvement or does not respond to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02956382 Active, not recruiting - Clinical trials for Refractory Follicular Lymphoma

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Start date: March 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.

NCT ID: NCT02568553 Active, not recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Start date: November 15, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement (relapsed). Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.

NCT ID: NCT01955499 Active, not recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Start date: September 24, 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of lenalidomide and ibrutinib in treating patients with B-cell non-Hodgkin lymphoma that has returned (relapsed) or not responded to treatment (refractory). Lenalidomide helps shrink or slow the growth of non-Hodgkin lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide with ibrutinib may work better in treating non-Hodgkin lymphoma than giving either drug alone.

NCT ID: NCT01849263 Active, not recruiting - Clinical trials for Recurrent Grade 1 Follicular Lymphoma

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

Start date: April 2, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ibrutinib works in treating patients with follicular lymphoma that has come back after a period of improvement or does not respond to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.